"While we continue to wholeheartedly support the Company's mission... it is also clear that we differ on the strategic direction for the Company going forward."
"I am surprised and disappointed by the decision of the directors to resign," Wojcicki wrote in her address to "Team 23," which was first reported by the Wall Street Journal.
"Outside of the short term pressures of the public markets, taking 23andMe private will still be the best opportunity for long term success."
Despite the challenges, Wojcicki has remained optimistic about 23andMe's future, discussing the company's new drug developments and how they could revitalize the brand.
Collection
[
|
...
]